FDA Brief

Warning letters Drugs

FDA warning letter to

Guangxi Yulin Pharmaceutical Group Co. Ltd.

High riskIssued Sep 30, 2025Posted Oct 21, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Guangxi Yulin Pharmaceutical Group that its OTC drugs lacked release testing and had data integrity failures.

What happened

FDA inspected the drug manufacturing facility in Yulin, Guangxi, China, from March 17 to 21, 2025. FDA found that the firm released drug products without testing identity and strength of active ingredients, did not show its test methods were suitable or equivalent to United States Pharmacopeia methods, lacked adequate stability data, and lacked controls to prevent deletion or alteration of lab data. FDA said the firm's response was inadequate and that some problems repeated from a 2016 inspection.

What FDA found

  1. Failed to test each batch for identity and strength of active ingredients before release.

    21 CFR 211.165(a)
  2. Failed to establish scientifically sound test methods and specifications, including showing equivalence to United States Pharmacopeia methods.

    21 CFR 211.160(b)
  3. Failed to have adequate stability data and a stability program to support the labeled shelf life.

    21 CFR 211.166(a)
  4. Lab computer systems lacked records of who changed data, and analysts could alter or delete files.

    21 CFR 211.68(b)

What FDA wants

Respond in writing within 15 working days describing what you have done to correct violations and prevent recurrence. FDA also recommends engaging a qualified CGMP consultant to perform a six-system audit before seeking resolution of compliance status.

Who should pay attention

  • U.S. buyers and distributors of OTC drugs from this firm
  • companies relying on Chinese Pharmacopeia methods for U.S. products
  • quality teams managing lab data integrity and supplier audits

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk